Medigene, clinical stage immuno-oncology company focusing on the development of T cell immunotherapies for cancer, entered into a service agreement with Cytovant Sciences to support process development activities for the manufacturing of dendritic cell (DC) vaccines.
The deal builds on Medigene’s license and cooperation agreements with Roivant/Cytovant which cover three TCR projects and Medigene’s DC vaccine program targeting WT-1 and PRAME in acute myeloid leukemia (AML) for Greater China, South Korea, and Japan.
In January, Medigene published positive final results from the open-label Phase I/II trial with its DC vaccine in 20 AML patients and Roivant/Cytovant is continuing the development of this program as CVT-DC-01 in its licensed territories in Asia.
Under the service agreement, Medigene will use its expertise to support Roivant/Cytovant in establishing processes for the manufacturing of the DC vaccine and further develop these towards an automated manufacturing process in the future.
“We are delighted to build further on the collaboration with Roivant/Cytovant which is proceeding well on multiple programs,” says Kai Pinkernell, MD, chief medical officer and chief developmental officer. “Following the positive final data from our DC trial, we are pleased to see our partners take the next steps to move the vaccine into further clinical development in Asia. Reliable manufacturing processes are crucial to ensure that the DC vaccines can be produced in compliance with all appropriate standards and we are pleased to provide our support.”
